Table 2. Evaluation of the quantitative level of anti-PGL-Tb1 and anti-ESAT-6/CFP10 antibodies in patients with active TB stratified by HIV status and center of enrolment.
HIV-infected | HIV-non-infected* | |||||
Median OD (IQR) | Median OD (IQR) | |||||
Center | N | PGL-Tb1 | ESAT-6/CFP10 | N | PGL-Tb1 | ESAT-6/CFP10 |
Hinduja | 50 | 0.161 (0.119–0.260) | 0.140 (0.084–0.203) | 190 | 0.107 (0.075–0.160) | 0.085 (0.060–0.109) |
AIIMS | 29 | 0.280 (0.169–0.458) | 0.127 (0.066–0.247) | 94 | 0.124 (0.071–0.441) | 0.079 (0.049–0.146) |
Safdarjung | 1 | 0.845 (0.845–0.845) | 0.310 (0.310–0.310) | 119 | 0.096 (0.055–0.182) | 0.062 (0.035–0.091) |
JALMA | 0 | NA | NA | 99 | 0.144 (0.091–0.255) | 0.063 (0.038–0.101) |
NIMS | 4 | 0.301 (0.107–0.664) | 0.133 (0.068–0.250) | 49 | 0.118 (0.060–0.210) | 0.054 (0.032–0.107) |
TRC | 18 | 0.173 (0.088–0.417) | 0.094 (0.058–0.192) | 125 | 0.103 (0.069–0.172) | 0.067 (0.52–0.090) |
Footnotes: TB: tuberculosis; HIV: human immunodeficiency virus; LTBI: latent tuberculosis infection; N; number of serum tested; OD: optical density; IQR (interquartile range).
*HIV non-infected corresponds to the true HIV-uninfected and HIV-unknown patients with active TB.